Drug intelligence / Profile preview

Maidang Rutong Granules

Development stage: Unknown
Lead developer: Anqing Echo Biopharmaceutical
Administration: Oral

Overview

Maidang Rutong Granules (麦当乳通颗粒) is a Traditional Chinese Medicine (TCM) pharmaceutical product developed and manufactured by Anqing Echo Biopharmaceutical, a subsidiary of the Echo Biopharmaceutical Group. The product is formulated as oral granules and is primarily composed of extracts from *Medicago sativa* (Alfalfa), which is known in certain Chinese dialects as "Maidang." It is specifically indicated for the treatment of postpartum insufficient lactation (hypogalactia), acting to promote and increase milk secretion in nursing mothers. The drug has received regulatory approval in China and is part of Echo Biopharmaceutical's established portfolio of maternal and child health products.

Brand names: Maidang Rutong Granules
Other names: 麦当乳通颗粒Maidang Rutong Keli

Beyond the preview

Go deeper on Maidang Rutong Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maidang Rutong Granules.

Explore the full profile